Cargando…

Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass

Detalles Bibliográficos
Autores principales:	Radovits, Tamás, Korkmaz, Sevil, Loganathan, Sivakkanan, Stasch, Johannes-Peter, Karck, Matthias, Szabó, Gábor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313370/ http://dx.doi.org/10.1186/1471-2210-9-S1-P56

Ejemplares similares

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
por: Scheerans, Christian, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

Pharmacological activation of soluble guanylate cyclase activator protects the heart against isoproterenol-induced myocardial ischemia in rats
por: Korkmaz, Sevil, et al.
Publicado: (2009)

The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
por: Mátyás, Csaba, et al.
Publicado: (2015)

The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
por: Irvine, Jennifer C., et al.
Publicado: (2012)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

Phosphodiesterase-5 inhibition delays cardiac dilation and improves myocardial function in a rat model of heart failure due to chronic volume overload
por: Loganathan, Sivakkanan, et al.
Publicado: (2009)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

BAY 58-2667, an NO-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
por: Krieg, Thomas, et al.
Publicado: (2009)

Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat
por: Kollau, Alexander, et al.
Publicado: (2017)

Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011)

Comparison of the Reverse-Remodeling Effect of Pharmacological Soluble Guanylate Cyclase Activation With Pressure Unloading in Pathological Myocardial Left Ventricular Hypertrophy
por: Ruppert, Mihály, et al.
Publicado: (2019)

Bone Marrow Culture-Derived Conditioned Medium Recovers Endothelial Function of Vascular Grafts following In Vitro Ischemia/Reperfusion Injury in Diabetic Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2022)

Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs
por: Næsheim, Torvind, et al.
Publicado: (2020)

Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation
por: Benke, Kálmán, et al.
Publicado: (2020)

Graft Preservation Solution DuraGraft(®) Alleviates Vascular Dysfunction Following In Vitro Ischemia/Reperfusion Injury in Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Conditioned Medium from Mesenchymal Stem Cells Alleviates Endothelial Dysfunction of Vascular Grafts Submitted to Ischemia/Reperfusion Injury in 15-Month-Old Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Improvement of Left Ventricular Graft Function Using an Iron-Chelator-Supplemented Bretschneider Solution in a Canine Model of Orthotopic Heart Transplantation
por: Szabó, Gábor, et al.
Publicado: (2022)

Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains
por: Rehan Khalid, Rana, et al.
Publicado: (2018)

Mesenchymal stem cell-derived conditioned medium protects vascular grafts of brain-dead rats against in vitro ischemia/reperfusion injury
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Aspirin Reduces Ischemia-Reperfusion Injury Induced Endothelial Cell Damage of Arterial Grafts in a Rodent Model
por: Veres, Gábor, et al.
Publicado: (2022)

Left-ventricular hypertrophy in 18-month-old donor rat hearts was not associated with graft dysfunction in the early phase of reperfusion after cardiac transplantation–gene expression profiling
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Acute Ethanol Exposure Increases the Susceptibility of the Donor Hearts to Ischemia/Reperfusion Injury after Transplantation in Rats
por: Li, Shiliang, et al.
Publicado: (2012)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2021)

Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload
por: Németh, Balázs Tamás, et al.
Publicado: (2016)

Cinaciguat (BAY-582667) Modifies Cardiopulmonary and Systemic Circulation in Chronically Hypoxic and Pulmonary Hypertensive Neonatal Lambs in the Alto Andino
por: Beñaldo, Felipe A., et al.
Publicado: (2022)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats
por: Czirok, Szabina, et al.
Publicado: (2017)

Effects of inosine on reperfusion injury after cardiopulmonary bypass
por: Veres, Gábor, et al.
Publicado: (2010)

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
por: Sayour, Alex Ali, et al.
Publicado: (2019)

Comparison of donor hearts from hypoxic cardiac arrest followed by warm ischemia and from exsanguination as non-beating donor models in rat heart transplantation
por: Li, Shiliang, et al.
Publicado: (2015)

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
por: Mitrovic, Veselin, et al.
Publicado: (2009)

Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass
por: Veres, Gábor, et al.
Publicado: (2015)

Preservation solution Custodiol containing human alpha-1-antitrypsin improves graft recovery after prolonged cold ischemic storage in a rat model of heart transplantation
por: Korkmaz-Icöz, Sevil, et al.
Publicado: (2023)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells
por: Hoffmann, Linda S., et al.
Publicado: (2011)

Infusion of sodium sulfide improves myocardial and endothelial function in a canine model of cardiopulmonary bypass
por: Szabó, C, et al.
Publicado: (2007)

Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
por: Hoffmann, Linda S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r82ri2fn5bmu6pd8b8fkq1qutj